177Lu-Vipivotide Tetraxetan (177Lu-PSMA-617, Pluvicto) Therapy

被引：1
|
作者：
Clements, Sarah
Tempesta, Daniel
Jacene, Heather
机构：
来源：
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | 2022年 / 50卷 / 03期
关键词：
D O I：
10.2967/jnmt.122.264731
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
[No abstract available]
引用
收藏
页码：213 / 214
页数：2
相关论文
共 50 条
  • [21] Cocktail Therapy of 177Lu-PSMA-617 and 177Lu-EDTMP in Patients With mCRPC A Proof-of-Principle Application
    Bal, Chandrasekhar
    Yadav, Madhav Prasad
    Ballal, Sanjana
    CLINICAL NUCLEAR MEDICINE, 2016, 41 (08) : E386 - E387
  • [22] 177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response
    Kambiz Rahbar
    Martin Bögemann
    Hojjat Ahmadzadehfar
    European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 166 - 167
  • [23] 177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response
    Rahbar, Kambiz
    Boegemann, Martin
    Ahmadzadehfar, Hojjat
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (01) : 166 - 167
  • [24] Peptide Receptor Radionuclide Therapy (PRRT) with Lu-177 PSMA-617 Vipivotide Tetraxetan (Pluvicto) on a recently diagnosed prostatic cancer as initial first line therapy.
    Arroyo, Alberto
    Semaan, Hassan
    Dresel, Stefan
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64
  • [25] Initial Experience with 177Lu-PSMA-617 Therapy: Toxicity and Outcomes PostApproval
    Tuchayi, Abuzar Moradi
    Kim, Sarasa
    Morley, Amanda
    Saelee, Rachelle
    Wang, Yingbing
    Heath, Courtney Lawhn
    Juarez, Roxanna
    Hope, Thomas
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64
  • [26] Preclinical dosimetric studies of 177Lu-scFvD2B and comparison with 177Lu-PSMA-617 and 177Lu-iPSMA endoradiotherapeutic agents
    Melendez-Alafort, Laura
    Ferro-Flores, Guillermina
    Santos-Cuevas, Clara
    Ocampo-Garcia, Blanca
    Turato, Sofia
    Fracasso, Giulio
    Bolzati, Cristina
    Rosato, Antonio
    De Nardo, Laura
    MEDICAL PHYSICS, 2021, 48 (07) : 4064 - 4074
  • [27] Renal Function after Radioligand Treatment with 177Lu-PSMA-617
    Ngoc, Christina Nguyen
    Happel, Christian
    Davis, Karen
    Groener, Daniel
    Mader, Nicolai
    Mandel, Philipp
    Tselis, Nikolaos
    Gruenwald, Frank
    Sabet, Amir
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [28] Evaluation of 177Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective 177Lu-PSMA-617 and NOX66 Combination Trial (LuPIN)
    Pathmanandavel, Sarennya
    Crumbaker, Megan
    Ho, Bao
    Yam, Andrew O.
    Wilson, Peter
    Niman, Remy
    Ayers, Maria
    Sharma, Shikha
    Hickey, Adam
    Eu, Peter
    Stockler, Martin
    Martin, Andrew J.
    Joshua, Anthony M.
    Nguyen, Andrew
    Emmett, Louise
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (02) : 221 - 226
  • [29] Production and radiochemical purity of 177Lu-PSMA-617 for clinical trial
    Asad, Ali
    Scharli, Rainer
    Morandeau, Laurence
    Price, Roger
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2019, 62 : S527 - S527
  • [30] 177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response Reply
    Yadav, Madhav Prasad
    Ballal, Sanjana
    Tripathi, Madhavi
    Bal, Chandrasekhal
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (01) : 168 - 169
12345